Table 1.
Patient characteristics (n = 188)
| Parameters | No. (%) | Mean ± SEM |
|---|---|---|
| Age (years) | 56.5 ± 0.8 | |
| Stage | ||
| I | 22 (11.7%) | |
| II | 125 (66.5%) | |
| III | 37 (19.7%) | |
| IV | 4 (2.1%) | |
| Smoking | ||
| No | 173 (92.0%) | |
| Yes | 15 (8.0%) | |
| Pelvic lymphadenopathy on CT scan | ||
| No | 167 (88.8%) | |
| Yes | 21 (11.2%) | |
| Parametrial scores | ||
| 0 | 36 (19.1%) | |
| 1-3 | 103 (54.8%) | |
| 4-6 | 49 (26.1%) | |
| Hemoglobin (g/dL) | 11.1 ± 0.2 | |
| Field size (Y-axis) (cm) | 18.3 ± 0.1 | |
| HDR dose to point A (Gy) | 24.3 ± 0.2 | |
| RT duration (days) | 61.2 ± 1.1 | |
| Pretreatment SCC-Ag level (ng/mL) | 15.2 ± 2.3 | |
| < 2 | 60 (31.9%) | |
| 2-10 | 68 (36.2%) | |
| 10-20 | 21 (11.6%) | |
| 20-40 | 21 (11.6%) | |
| ≥ 40 | 18 (9.6%) | |
| Pretreatment CEA level (ng/mL) | 7.7 ± 1.7 | |
| < 5 | 149 (79.3%) | |
| 5-10 | 16 (8.5%) | |
| ≥ 10 | 23 (12.2%) | |
| EBRT technique | ||
| AP/PA | 2 (1.1%) | |
| Four-field | 174 (92.6%) | |
| IMRT | 12 (6.4%) | |
| EBRT dose (Gy) | ||
| Central dose | 42.2 ± 0.3 | |
| Parametrial dose | 47.2 ± 0.4 |